Clinical Trial Update: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating atezolizumab and/or bevacizumab with or without standard chemotherapy as second-line treatment for advanced head and neck cancers; AC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Carcinoma
• Laryngeal Cancer
• Lip and Oral Cavity Cancer
• Nasal Cavity Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Oropharyngeal Carcinoma
• Pharyngeal Squamous Cell Carcinoma
• Sinonasal Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING